New cancer drug begins human testing for Tough-to-Treat tumors
NCT ID NCT06685068
Summary
This early-stage trial is testing a new drug called GEN1286 in adults with advanced solid tumors that have spread or returned after other treatments. The main goals are to find a safe dose and see if the drug can help shrink tumors. The study is divided into two parts: first finding the right dose, and then testing that dose in specific groups of patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
START San Antonio
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.